MD
MDGL.US Madrigal Pharmaceuticals Inc
- Market cap
- USD 9.93B
- P/E
- -
- P/B
- 15.84x
- ROE
- -20.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MDGL.US undervalued?
Graham numberThe Graham number of Madrigal Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Madrigal Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Madrigal Pharmaceuticals Inc yet.
Madrigal Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Full company profileMadrigal Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Madrigal Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 350K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180M | 958M | 1.48B |
| Gross Profit | -156.00 | 350K | -96.0K | -112K | -471K | 0.00 | 0.00 | 0.00 | 174M | 902M | 1.34B |
| Operating Income | -25.2M | -32.1M | -40.7M | -95.0M | -207M | -242M | -294M | -380M | -498M | -300M | -124M |
| EBITDA | -25.2M | -32.0M | -40.6M | -94.9M | -206M | -242M | -291M | -360M | -450M | -264M | -95.9M |
| Net Income | -26.4M | -31.2M | -32.8M | -72.8M | -197M | -241M | -295M | -374M | -466M | -288M | -129M |
| EPS | -5.07 | -2.54 | -2.22 | -4.73 | -13 | -15 | -17 | -20 | -22 | -13 | -4.26 |
| Balance Sheet | |||||||||||
| Total Assets | 41.2M | 192M | 485M | 442M | 287M | 273M | 363M | 641M | 1.04B | 1.26B | 1.43B |
| Total Liabilities | 4.80M | 10.1M | 8.44M | 25.5M | 47.0M | 77.2M | 165M | 235M | 288M | 657M | 807M |
| Shareholders' Equity | 36.4M | 182M | 477M | 417M | 240M | 196M | 197M | 405M | 754M | 603M | 627M |
| Cash & Short-term Investments | 40.5M | 192M | 484M | 439M | 284M | 270M | 359M | 634M | 926M | 984M | 961M |
| Total Debt | - | - | - | 676K | 786K | 797K | 49.9M | 117M | 120M | 354M | 354M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.6M | -22.3M | -25.5M | -41.6M | -158M | -184M | -225M | -324M | -456M | -190M | -31.4M |
| Capital Expenditure | 3.08K | 125K | 22.0K | 172K | 334K | 209K | 217K | 1.48M | 1.46M | 467K | 16.0M |
| Free Cash Flow | -17.6M | -22.4M | -25.5M | -41.8M | -158M | -184M | -225M | -326M | -457M | -190M | -47.4M |
| Ratios | |||||||||||
| ROE | -72.5% | -17.1% | -6.9% | -17.5% | -82.3% | -122.9% | -149.6% | -92.2% | -61.8% | -47.8% | -20.6% |
| ROA | -64.0% | -16.2% | -6.8% | -16.5% | -68.8% | -88.2% | -81.5% | -58.3% | -44.7% | -22.9% | -9.0% |
| Net Profit Margin | - | -8,901.1% | - | - | - | - | - | - | -258.6% | -30.1% | -8.8% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.25x | 0.29x | 0.16x | 0.59x | 0.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Madrigal Pharmaceuticals Inc dividends
Madrigal Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:35 on Jul 25, 2016.
Who owns Madrigal Pharmaceuticals Inc
- Insiders 6.42%
- Institutions 93.58%
- Public & others 0.00%
- Shares outstanding 23.2M
- Free float 14.0M
Top funds holding MDGL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 639K | 2.75% | +22.37% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 588K | 2.53% | +0.27% | Sep 2026 |
| Vanguard Small Cap Index | 416K | 1.79% | -1.96% | Sep 2026 |
| Polar Capital Biotech S Inc | 350K | 1.50% | 0.00% | Sep 2026 |
| Janus Henderson Forty S | 339K | 1.46% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 290K | 1.25% | +2.69% | Oct 2026 |
| Janus Henderson Enterprise D | 233K | 1.00% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 232K | 1.00% | -4.88% | Sep 2026 |
| First Trust NYSE Arca Biotech ETF | 208K | 0.89% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 199K | 0.86% | +9.12% | Sep 2026 |
| iShares Biotechnology ETF | 167K | 0.72% | -0.35% | Oct 2026 |
| Janus Henderson Global Life Sciences D | 154K | 0.66% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 150K | 0.65% | +9.09% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 148K | 0.64% | +2.66% | Aug 2026 |
| Lord Abbett Growth Leaders I | 139K | 0.60% | 0.00% | Sep 2026 |
| Invesco Discovery A | 134K | 0.58% | +1.77% | Sep 2026 |
| Janus Henderson Contrarian D | 122K | 0.53% | 0.00% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 106K | 0.45% | +12.13% | Jun 2026 |
| Schwab US Small-Cap ETF™ | 105K | 0.45% | +0.21% | Oct 2026 |
| Pictet-Biotech P USD | 101K | 0.43% | -7.75% | Jul 2026 |
Top institutions holding MDGL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 2.14M | 9.23% | +0.07% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.99M | 8.58% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 1.94M | 8.33% | 0.00% | Jun 2026 |
| venBio Select Advisor LLC | 1.83M | 7.89% | +0.83% | Jun 2026 |
| Paulson & Company Inc | 1.34M | 5.77% | -3.75% | Jun 2026 |
| BlackRock Inc | 1.20M | 5.17% | -23.03% | Jun 2026 |
| Vanguard Capital Management, LLC | 836K | 3.60% | +1.03% | Jun 2026 |
| Wellington Management Company LLP | 826K | 3.55% | +18.81% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 782K | 3.37% | -7.06% | Jun 2026 |
| State Street Corp | 527K | 2.27% | -13.53% | Jun 2026 |
| Citadel Advisors Llc | 507K | 2.18% | +11.76% | Jun 2026 |
| UBS Group AG | 402K | 1.73% | +241.07% | Jun 2026 |
| Geode Capital Management, LLC | 375K | 1.61% | -17.77% | Jun 2026 |
| FMR Inc | 356K | 1.53% | -30.39% | Jun 2026 |
| William Blair Investment Management, LLC | 324K | 1.40% | -4.82% | Jun 2026 |
| Amvescap Plc. | 301K | 1.30% | -8.52% | Jun 2026 |
| Armistice Capital, LLC | 288K | 1.24% | +8.85% | Jun 2026 |
| Lord, Abbett & Co LLC | 282K | 1.21% | +15.97% | Jun 2026 |
| Assenagon Asset Management SA | 248K | 1.07% | +1,449.48% | Jun 2026 |
| The Goldman Sachs Group Inc | 246K | 1.06% | -11.21% | Jun 2026 |
Madrigal Pharmaceuticals Inc company profile
- Company name
- Madrigal Pharmaceuticals Inc
- Ticker
- MDGL.US
- Exchange
- USA Stocks
- Listed since
- Feb 6, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 915
- Fiscal year end
- December
- Address
- 1001 Conshohocken State Road, West Conshohocken, PA, United States, 19428
- Phone
- 267 824 2827
- Website
- madrigalpharma.com
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals Inc management
10- Mr. William J. SiboldCEO, President & Director · born 1966
- Dr. Rebecca A. Taub M.D.Founder, Senior Scientific & Medical Advisor and Director · born 1952
- Ms. Mardi C. DierExecutive VP & CFO · born 1964
- Ms. Shannon KelleyExecutive VP, Chief Legal Officer & Corporate Secretary · born 1975
- Ms. Carole HuntsmanExecutive VP & Chief Commercial Officer · born 1965
- Dr. David Soergel M.D.Executive VP & Chief Medical Officer · born 1968
- Mr. Mark UnderwoodExecutive Vice President of Business Planning & Operations
- Ms. Rita ThakkarSenior VP & Chief Accounting Officer · born 1974
- Mr. Ronald FilippoExecutive VP & Chief Information Officer
- Ms. Tina E. VenturaChief Investor Relations Officer